Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$7.80 USD

7.80
1,566,958

+0.12 (1.56%)

Updated May 9, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk

by Kinjel Shah

Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.

Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered

by Zacks Equity Research

Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.

Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results

by Zacks Equity Research

Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.

Sheraz Mian headshot

Top Research Reports for Chevron, NextEra Energy & Chubb

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), NextEra Energy, Inc. (NEE) and Chubb Limited (CB).

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.

Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall

by Zacks Equity Research

Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.

Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies

by Zacks Equity Research

Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates

by Kinjel Shah

FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.

Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag

by Zacks Equity Research

Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates

by Kinjel Shah

Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.

Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline

by Zacks Equity Research

Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

Unity (UNX) Down on Disappointing Results From Wet AMD Study

by Zacks Equity Research

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

Regeneron (REGN) Gets Label Extension for Cholesterol Drug

by Zacks Equity Research

Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.

Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?

by Zacks Equity Research

Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.

Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

by Zacks Equity Research

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Verona (VRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.

Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.

Acer (ACER) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.